Conflicting signals from drug regulator, COVID-19 task force
The Hindu
On a few occasions, the national COVID-19 task force has refused to include drugs and vaccines that have been granted an EUA by the regulator
On December 28 last year, Health Minister Mansukh Mandaviya tweeted saying that in further strengthening the fight against COVID-19, the Indian drug regulator has granted emergency use approval for the antiviral drug molnupiravir. He also mentioned that molnupiravir will be manufactured by 13 generic drug manufacturers in India.
“Considering the emergency and unmet medical need in COVID-19, the SEC on December 27 recommended for grant of permission to manufacture and market molnupiravir for restricted use under emergency situation in the country for treatment of adult patients with COVID-19,” the drug regulator said in a statement.
A week later, on January 5, at a press conference, the Director-General of ICMR Dr. Balram Bhargava said molnupiravir has major safety concerns and therefore was not included in the national protocol for treatment of coronavirus.

NPCIL is to blame for storage of radioactive waste on site of Kudankulam nuclear power plant: Appavu
Tamil Nadu Speaker Appavu criticizes NPCIL for unsafe nuclear waste storage at Kudankulam, urging better solutions for public safety.












